A questionnaire survey of physicians' perspectives regarding the assessment of chemotherapy-induced peripheral neuropathy in patients with breast cancer

Japanese Journal of Clinical Oncology

Volumn 38, Issue 11, 2008, Pages 748-754

  Kuroi, Katsumasa ^a   Shimozuma, Kojiro ^b   Ohashi, Yasuo ^c   Takeuchi, Ayano ^c   Aranishi, Toshihiko ^c   Morita, Satoshi ^d   Ohsumi, Shozo ^e   Watanabe, Toru ^f   Bain, Stacey ^g   Hausheer, Frederick H ^g  

^a TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^b RITSUMEIKAN UNIVERSITY   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^e NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^f Hamamatsu City Med Ctr Devmtl M   (Japan)

^g BioNumrik Pharmaceuticals Inc   (United States)

Author keywords

Breast cancer; Chemotherapy; Neuropathy; Patient reported outcome; Questionnaire

Indexed keywords

ANTINEOPLASTIC AGENT; TAXANE DERIVATIVE;

ADULT; AGED; ARTICLE; BREAST CANCER; BURN; CANCER ADJUVANT THERAPY; CLIMBING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DIAGNOSTIC VALUE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEEDING; FEMALE; FOLLOW UP; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MOTOR DYSFUNCTION; MOTOR NEUROPATHY; MUSCLE WEAKNESS; NEUROTOXICITY; PAIN; PARESTHESIA; PATIENT ASSESSMENT; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PHYSICIAN; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; SIDE EFFECT; SKIN TINGLING; SOMATOSENSORY DISORDER; SYMPTOMATOLOGY; WALKING DIFFICULTY; WORK CAPACITY;

ACTIVITIES OF DAILY LIVING; ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG THERAPY; FEMALE; HEALTH CARE SURVEYS; HUMANS; MALE; MIDDLE AGED; PERIPHERAL NERVOUS SYSTEM DISEASES; PHYSICIANS; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX;

EID: 55149102843     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyn100     Document Type: Article

References (17)

1. Kuroi K, Shimozuma K. Neurotoxicity of taxanes: Symptoms and quality of life assessment. Breast Cancer 2004;11:92-9.
2. Hausheer FH, Schilsky RL, Bain S, Berghorn EJ, Lieberman F. Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol 2006;33:15-49.
3. Mielke S, Sparreboom A, Mross K. Peripheral neuropathy: A persisting challenge in paclitaxel-based regimes. Eur J Cancer 2006;42: 24-30.
4. Visovsky C, Collins M, Abbott L, Aschenbrenner J, Hart C. Putting evidence into practice: Evidence-based interventions for chemotherapy-induced peripheral neuropathy. Clin J Oncol Nurs 2007;11:901-13.
5. Postma TJ, Heimans JJ, Muller MJ, Ossenkoppele GJ, Vermorken JB, Aaronson NK. Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Ann Oncol 1998;9: 739-44.
6. Cavaletti G, Bogliun G, Marzorati L, et al. Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale. Neurology 2003;61:1297-300.
7. Basch E, Iasonos A, McDonough T, et al. Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: Results of a questionnaire-based study. Lancet Oncol 2006;7:903-9.
8. Stephens RJ, Hopwood P, Girling DJ, Machin D. Randomized trials with quality of life endpoints: Are doctors' ratings of patients' physical symptoms interchangeable with patients' self-ratings? Qual Life Res 1997;6:225-36.
9. Shimozuma K, Ohashi Y, Takeuchi A, et al. Validation of the Patient Neurotoxicity Questionnaire (PNQ) during taxane chemotherapy in a phase III randomized trial of breast cancer: N-SAS BC 02. 27th SABCS (#6037), 2004.
10. Sloan JA, Berk L, Roscoe J, et al. Integrating patient-reported outcomes into cancer symptom management clinical trials supported by the National Cancer Institute-sponsored clinical trials networks. J Clin Oncol 2007;25:5070-7.
11. Garcia SF, Cella D, Clauser SB, et al. Standardizing patient-reported outcomes assessment in cancer clinical trials: A patient-reported outcomes measurement information system initiative. J Clin Oncol 2007;25:5106-12.
12. Shimozuma K, Ohashi Y, Takeuchi A, et al. Assessment and quantification of taxane-induced neurotoxicity in a phase III randomized trial of patients with breast cancer (AC followed by PAC/DOC vs. PAC/DOC alone): N-SAS BC 02. 42th ASCO (#8523), Altanta, 2006.
13. Shimozuma K, Ohashi Y, Takeuchi A, et al. Feasibility and validity of the Patient Neurotpxicity Questionnaire (PNQ) during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02. 2008, in preparation.
14. Hagiwara H, Sunada Y. Mechanism of taxane neurotoxicity. Breast Cancer 2004;11:82-5.
15. Trotti A, Colevas AD, Setser A, Basch E. Patient-reported outcomes and the evolution of adverse event reporting in oncology. J Clin Oncol 2007;25:5121-7.
16. Cella D, Peterman A, Hudgens S, Webster K, Socinski MA. Measuring the side effects of taxane therapy in oncology: The functional assessment of cancer therapy-taxane (FACT-taxane). Cancer 2003;98:822-31.
17. Calhoun EA, Welshman EE, Chang CH, et al. Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer 2003;13:741-8.